Andrew R. Glanzman - 10 Mar 2026 Form 4 Insider Report for CBRE GROUP, INC. (CBRE)

Reporting relationship: CEO, Real Estate Investments
Issuer ticker: CBRE
Reported as of: 10 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Mar 2026, 18:02:29 UTC
Prior SEC filing: 09 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Andria Iles, Attorney-in-Fact for Andrew R. Glanzman

Key filing fact

Andrew R. Glanzman filed Form 4 for CBRE GROUP, INC. (CBRE) on 12 Mar 2026.

Key facts

This page summarizes Andrew R. Glanzman's Form 4 filing for CBRE GROUP, INC. (CBRE).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Mar 2026, 18:02.

Change

Previous filing in this sequence was filed on 09 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002113511 Primary reporting owner

Glanzman Andrew R

Relationship: CEO, Real Estate Investments
Address: 2121 NORTH PEARL STREET, SUITE 300, DALLAS
Signature: /s/ Andria Iles, Attorney-in-Fact for Andrew R. Glanzman
Signature date: 12 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CBRE transaction

Class A Common Stock

Tax liability

Transaction value
Shares: -817
Change %: -1.4%
Price: $134.59^*
Shares after: 57,340
Date: 10 Mar 2026
Ownership: Direct

CBRE transaction

Class A Common Stock

Tax liability

Transaction value
Shares: -869
Change %: -1.5%
Price: $134.59^*
Shares after: 56,471
Date: 10 Mar 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .